Q3 2024 · 13F-HR
Vivo Capital, LLCholdings as filed
Filed 2024-11-13 · accession 0001213900-24-097589
$1.21B
Reported value
43
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 834203309 | SLNO | Soleno Therapeutics Inc | $317.7M | 26.3% | 6,291,851 | Common | SOLE |
| 374163103 | GERN | Geron Corp | $123.6M | 10.2% | 27,225,292 | Common | SOLE |
| 413197104 | HRMY | Harmony Biosciences Holdings Inc | $104.2M | 8.63% | 2,606,247 | Common | SOLE |
| 925050106 | VRNA | Verona Pharma PLC | $102.1M | 8.45% | 3,549,758 | Common | SOLE |
| P8696W104 | SVA | Sinovac Biotech Ltd. | $76.3M | 6.32% | 11,800,000 | Common | SOLE |
| 880881107 | 430 | Terns Pharmaceuticals Inc | $57.5M | 4.76% | 6,895,746 | Common | SOLE |
| 45783C200 | TIL | Instil Bio Inc | $42.0M | 3.48% | 624,339 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics Inc | $40.0M | 3.31% | 1,114,960 | Common | SOLE |
| 92790C104 | VRDN | Viridian Therapeutics Inc | $38.2M | 3.16% | 1,678,207 | Common | SOLE |
| G29687103 | AVDL | Avadel Pharmaceuticals PLC | $35.2M | 2.91% | 2,684,109 | Common | SOLE |
| 82686Q101 | SLN | Silence Therapeutics PLC | $20.1M | 1.66% | 1,105,454 | Common | SOLE |
| 98937L105 | ZBIO | Zenas Biopharma Inc | $20.0M | 1.66% | 1,183,260 | Common | SOLE |
| 29479A108 | ERAS | Erasca Inc | $18.4M | 1.53% | 6,756,756 | Common | SOLE |
| 68062P106 | OLMA | Olema Pharmaceuticals Inc | $18.0M | 1.49% | 1,505,862 | Common | SOLE |
| 04635X102 | CATBUSD | Astria Therapeutics Inc | $17.1M | 1.41% | 1,552,685 | Common | SOLE |
| 89157D105 | TRML | Tourmaline Bio Inc. | $15.2M | 1.26% | 591,882 | Common | SOLE |
| 76200L309 | RZLT | Rezolute Inc | $13.6M | 1.12% | 2,797,704 | Common | SOLE |
| 68622P109 | ORIC | Oric Pharmaceuticals Inc | $13.1M | 1.08% | 1,277,818 | Common | SOLE |
| 81749D107 | SERA | Sera Prognostics Inc | $12.9M | 1.07% | 1,650,440 | Common | SOLE |
| 19240Q201 | COGT | Cogent Biosciences Inc | $12.1M | 1.00% | 1,122,471 | Common | SOLE |
| 00289Y206 | ABEO | Abeona Therapeutics, Inc. | $11.6M | 0.96% | 1,842,751 | Common | SOLE |
| 20451W101 | CMPS | Compass Pathway PLC | $10.1M | 0.84% | 1,608,000 | Common | SOLE |
| 15102K100 | CELC | Celcuity Inc | $9.1M | 0.75% | 610,500 | Common | SOLE |
| 24661P807 | DCTH | Delcath Systems, Inc. | $9.0M | 0.75% | 997,005 | Common | SOLE |
| 221015100 | CRVS | Corvus Pharmaceuticals Holdings | $7.9M | 0.65% | 1,497,268 | Common | SOLE |
| 75915K309 | RGLS | Regulus Therapeutics Inc | $7.8M | 0.65% | 5,000,000 | Common | SOLE |
| 00166B105 | ALXO | ALX Oncology Holdings Inc | $7.3M | 0.61% | 4,034,522 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics Inc | $6.5M | 0.54% | 3,556,023 | Common | SOLE |
| 449778109 | IOBTQ | IO Biotech Inc | $6.5M | 0.54% | 6,173,439 | Common | SOLE |
| 00773U207 | AVU0 | Adverum Biotechnologies, Inc. | $5.8M | 0.48% | 833,333 | Common | SOLE |
| 89532M101 | TRVI | Trevi Therapeutics Inc | $5.4M | 0.45% | 1,612,903 | Common | SOLE |
| 92337C203 | VSTM | Verastem Inc | $4.6M | 0.38% | 1,538,461 | Common | SOLE |
| 29286M105 | — | Engene Holdings Inc. | $4.5M | 0.37% | 678,705 | Common | SOLE |
| 21833P301 | CRBP | Corbus Pharmaceuticals Holdings | $3.4M | 0.28% | 166,794 | Common | SOLE |
| 097702104 | BOLT1EUR | Bolt Therapeutics Inc | $2.3M | 0.19% | 3,521,291 | Common | SOLE |
| 01671P100 | ALLKGUSD | Allakos Inc | $1.9M | 0.16% | 2,956,110 | Common | SOLE |
| 90466Y103 | — | Unicycive Therapeutics | $1.8M | 0.15% | 4,470,152 | Common | SOLE |
| 01626L204 | ALGS | Aligos Therapeutics Inc | $1.2M | 0.10% | 141,879 | Common | SOLE |
| 192005106 | CDXS | Codexis, Inc | $1.2M | 0.10% | 388,144 | Common | SOLE |
| 23306J200 | — | DBV Technologies SA | $948,106 | 0.08% | 1,354,437 | Common | SOLE |
| 746964105 | QTTB | Q32 Bio Inc. | $917,343 | 0.08% | 20,559 | Common | SOLE |
| 88032L605 | TENX | Tenax Therapeutics Inc | $720,832 | 0.06% | 208,333 | Common | SOLE |
| 74019P207 | DTIL | Precision Biosciences Inc | $41,888 | 0.00% | 4,675 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.